ScreenPoint Medical has raised $16m to advance the global expansion of its artificial intelligence (AI) screening tool for breast cancer detection, with ongoing participation from Siemens Healthineers.
ScreenPoint and Siemens Healthineers have been collaborating since at least 2020, with ScreenPoint’s Transpara Breast AI tool integrated with systems including MAMMOMAT Inspiration.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Aside from Siemens Healthineers, $14m of the Netherlands-based company’s funding originated from VC firm Insight Partners and other existing investors, while $2m of the tranche came from non-dilutive research grants.
ScreenPoint’s Transpara Breast AI is designed to enhance the detection of breast cancer through 2D and 3D mammograms. The latest version of the tool gained US Food and Drug Administration (FDA) clearance in December 2024 and first obtained a European CE mark in 2018.
Commenting on the latest funding, ScreenPoint CEO Pieter Kroese said: “We are well-positioned to scale globally and accelerate the development of solutions that make care personal and powerful.”
ScreenPoint’s latest funding follows recent research publications demonstrating Transpara’s effectiveness. Published in the Lancet in January 2026, data from the Mammography Screening with Artificial Intelligence (MASAI) randomised controlled trial (RCT) demonstrated that Transpara contributed to a 12% reduction in the rate of interval cancers, with 27% fewer aggressive cancers (non-luminal A subtype).
Further research, published in Nature Medicine in March 2026, demonstrated that the use of Transpara decreased radiologists’ workloads by 63.6%, and improved cancer detection rates by 15.2%.
ScreenPoint has raised $33m in previous financing rounds, with the latest funding tranche bringing its total to $49m.
Alexandra Krumbügel, head of product line women’s health, X-ray products at Siemens Healthineers, said: “Our continued investment reflects our strong conviction that AI will play a defining role in the future of breast imaging.”
The application of AI is having a significant impact in the healthcare space, particularly in streamlining imaging workflows to advance diagnostic accuracy and reduce the time practitioners spend on MRI and related imaging protocols. According to a report by GlobalData, the combined AI market across healthcare was valued at $11.9bn in 2024 and is expected to reach a valuation of $57.4bn in 2029.
